ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report

Background: High risk hypertensive patients have an increased risk of developing cardiovascular complication. It is better to use a proven cardio protective drugs to reduce blood pressure in high risk hypertensive patients. Angiotensin II receptor Blocker (ARB) is one type of antihyper-tensive drugs...

Full description

Bibliographic Details
Main Authors: Alvin Nursalim, Yoga Yuniadi
Format: Article
Language:English
Published: Indonesian Heart Association 2013-06-01
Series:Majalah Kardiologi Indonesia
Subjects:
Online Access:http://ijconline.id/index.php/ijc/article/view/59
_version_ 1818217596688793600
author Alvin Nursalim
Yoga Yuniadi
author_facet Alvin Nursalim
Yoga Yuniadi
author_sort Alvin Nursalim
collection DOAJ
description Background: High risk hypertensive patients have an increased risk of developing cardiovascular complication. It is better to use a proven cardio protective drugs to reduce blood pressure in high risk hypertensive patients. Angiotensin II receptor Blocker (ARB) is one type of antihyper-tensive drugs with cardioprotective effect for hypertensive patients without other risk factor. Whether cardioprotective effect of ARB also apply for a more specific population such as high risk hypertensive patients need to be investigated. Aim: To determine the efficacy of ARB compared to non-ARBs in preventing cardiac event in a more specific population, such as high risk hypertensive patients. Methods: A search was conducted on PubMed and Cochrane. The selection of title and abstract was done using inclusion and exclusion criterias. Three original articles were found and used as the evidence tor the clinical question. The selected studies were critically appraised for validity, importance and applicability. Result: According to Sawada et al, the blood pressure lowering effect was similar between valsartan and non-ARB groups. The cardiovascular events in valsartan group is lower compared to non-ARB groups (relative risk: 0.54, 95% confidence interval 0.4-0.7, p< 0.001). The administration of valsartan as compared to non-ARB, also reduce the occurence of angina pectoris (Relative risk: 0.52, 95% Confidence Interval 0.310.86, P=0.01058). Cohn JN et al showed that there was no significant differences in the candesartan group in terms of total death and primary endpoints. The only significant finding in this article was the lower rate of diabetes mellitus in the candesartan group. Conclusion: Valsartan, as compared to non-ARB, reduce cardic event in high risk hypertensive patients.
first_indexed 2024-12-12T07:10:23Z
format Article
id doaj.art-b003a42e1b754c1caad2d1d712f57c72
institution Directory Open Access Journal
issn 0126-3773
2620-4762
language English
last_indexed 2024-12-12T07:10:23Z
publishDate 2013-06-01
publisher Indonesian Heart Association
record_format Article
series Majalah Kardiologi Indonesia
spelling doaj.art-b003a42e1b754c1caad2d1d712f57c722022-12-22T00:33:38ZengIndonesian Heart AssociationMajalah Kardiologi Indonesia0126-37732620-47622013-06-0133210.30701/ijc.v33i2.59ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case ReportAlvin Nursalim0Yoga Yuniadi1Faculty of Medicine University of IndonesiaDepartement of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, and National Cardiovascular Center Harapan Kita, JakartaBackground: High risk hypertensive patients have an increased risk of developing cardiovascular complication. It is better to use a proven cardio protective drugs to reduce blood pressure in high risk hypertensive patients. Angiotensin II receptor Blocker (ARB) is one type of antihyper-tensive drugs with cardioprotective effect for hypertensive patients without other risk factor. Whether cardioprotective effect of ARB also apply for a more specific population such as high risk hypertensive patients need to be investigated. Aim: To determine the efficacy of ARB compared to non-ARBs in preventing cardiac event in a more specific population, such as high risk hypertensive patients. Methods: A search was conducted on PubMed and Cochrane. The selection of title and abstract was done using inclusion and exclusion criterias. Three original articles were found and used as the evidence tor the clinical question. The selected studies were critically appraised for validity, importance and applicability. Result: According to Sawada et al, the blood pressure lowering effect was similar between valsartan and non-ARB groups. The cardiovascular events in valsartan group is lower compared to non-ARB groups (relative risk: 0.54, 95% confidence interval 0.4-0.7, p< 0.001). The administration of valsartan as compared to non-ARB, also reduce the occurence of angina pectoris (Relative risk: 0.52, 95% Confidence Interval 0.310.86, P=0.01058). Cohn JN et al showed that there was no significant differences in the candesartan group in terms of total death and primary endpoints. The only significant finding in this article was the lower rate of diabetes mellitus in the candesartan group. Conclusion: Valsartan, as compared to non-ARB, reduce cardic event in high risk hypertensive patients.http://ijconline.id/index.php/ijc/article/view/59Angiotensin II receptor blockervalsartanhigh risk hypertensioncardiovascular complication
spellingShingle Alvin Nursalim
Yoga Yuniadi
ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
Majalah Kardiologi Indonesia
Angiotensin II receptor blocker
valsartan
high risk hypertension
cardiovascular complication
title ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
title_full ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
title_fullStr ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
title_full_unstemmed ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
title_short ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
title_sort arb compared with non arb in preventing cardiac events in high risk hypertensive patients an evidence based case report
topic Angiotensin II receptor blocker
valsartan
high risk hypertension
cardiovascular complication
url http://ijconline.id/index.php/ijc/article/view/59
work_keys_str_mv AT alvinnursalim arbcomparedwithnonarbinpreventingcardiaceventsinhighriskhypertensivepatientsanevidencebasedcasereport
AT yogayuniadi arbcomparedwithnonarbinpreventingcardiaceventsinhighriskhypertensivepatientsanevidencebasedcasereport